Therefore, pharmacotherapies to reduce body weight are being vigorously pursued, and amylin as well as DACRAs are emerging as potential novel anti-obesity drug candidates, especially in combination with other body weight-lowering gastrointestinal peptides. This evidence concerns the gene IAPP and obesity due to melanocortin 4 receptor deficiency.